Profiling the cancer genome to optimize the management of solid tumor treatments
The Homologous Recombination Solution™ (HRS) by SOPHiA GENETICS is a molecular diagnostic application that bundles a capture-based target enrichment kit with the analytical power of SOPHiA™ AI and full access to SOPHiA DDM® platform.
The solution was expertly designed to accurately characterize the genomic alterations associated with homologous recombination deficiency in regard to DNA damage response pathway. This solution is widely used for breast, ovarian, prostate and pancreatic cancers.
As they can be present at very low levels, detection of genomic alterations remains a difficult task. The HRS by SOPHiA GENETICS ensures the detection of genomic alterations at the low variant fraction.
Benefits of the solution
Detection of SNVs1 and Indels2 in all the genes of the panel
Clinical-grade analytical performance
Compatible with market-leading sequencing platforms without impact on performance. The gene panel can also be adapted according to experts' needs
1: SNVs: single nucleotide variants
2: Indels: insertions and deletions